Log in or Sign up for Free to view tailored content for your specialty!
Spondyloarthropathies News
Men with inflammatory joint diseases have more children than those without IJDs
Men with inflammatory joint diseases have more children and are less likely to be childless, compared with those without inflammatory joint diseases, according to data published in the Annals of the Rheumatic Diseases.
Drug costs and nocebo risks: Navigating the Humira ‘biosimilar boom’ 1 year later
A lot can change in a year. But has it?
Log in or Sign up for Free to view tailored content for your specialty!
Axial spondyloarthritis can be ‘reliably diagnosed’ shortly after chronic back pain onset
Most patients with recent-onset chronic back pain suspected of axial spondyloarthritis can be “unequivocally and reliably diagnosed” at their first rheumatology visit, according to data published in the Annals of the Rheumatic Diseases.
Conversion initiative gives ‘significant’ boost to Remicade biosimilar use
An initiative to switch clinically stable patients from Remicade to a biosimilar significantly increased biosimilar use in rheumatology and gastroenterology clinics within the University of North Carolina health system, according to data.
EULAR: Physical activity, regular assessment recommended for fatigue in inflammatory RMD
Fatigue in patients with inflammatory rheumatic and musculoskeletal diseases should be addressed with tailored physical activity, psychoeducational interventions or possibly immunomodulatory treatment, according to EULAR recommendations.
FDA approves Indocin oral suspension generic for inflammatory conditions
The FDA has approved an abbreviated new drug application from ANI Pharmaceuticals for indomethacin oral suspension, a generic version of Indocin oral suspension, according to a press release from the manufacturer.
Poverty, chronic inflammation have ‘synergistic’ impact driving all-cause, cancer mortality
Poverty and chronic inflammation together may have a “synergistic” impact leading to higher all-cause mortality, including a 127% increased heart disease mortality risk and a 196% higher risk for cancer mortality, according to data.
CVS Caremark to replace Humira with biosimilars on national commercial formularies
CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national commercial formularies effective April 1 in favor of biosimilar options, according to a press release from the company.
Satisfaction low with mandatory transition from Humira to biosimilar in New Zealand
Patients reported low overall satisfaction with New Zealand’s mandatory nationwide transition to an adalimumab biosimilar, though most said they are still taking it and appreciated its less-painful injections, according to a study.
Obstetric outcomes unaffected by maintaining TNF inhibition during pregnancy
SAN DIEGO — In patients with chronic rheumatic inflammatory disease, those who continue TNF inhibition during pregnancy have similar obstetrical outcomes as those who cease treatment, according to data presented at ACR Convergence 2023.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read